Riskpilot← Back to searchSign inGet full accessØresund Pharma ApS
APSActiveCVR 39492059Orient Plads 1Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201821 employeeswww.oresundpharma.com
Revenue 2025
DKK 39,7M
0% vs 2024
EBITDA margin
33.7%
-33% vs 2024
Equity ratio
35.0%
Financial strength
Net profit 2025
DKK 6,5M
-53% vs 2024
| Revenue | DKK 39,7M | +0% |
| EBITDA | DKK 13,4M | -33% |
| Net profit | DKK 6,5M | -53% |
| Total assets | DKK 127,6M | +57% |
| Equity | DKK 44,6M | +17% |
| Employees | 21 | — |
Legal name
Øresund Pharma ApS
CVR number
39492059
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17. april 2018
Share capital
DKK 55.600
Employees
21 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør alene
Company purpose
Selskabets formål er at udvikle og kommercialisere farmaceutiske lægemidler og dermed forbunden virksomhed.
Address
Orient Plads 1
Phone
+4540763916
Email
info@oresundpharma.com
Website
www.oresundpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 437 | 4.932 | 2.755 | 7.275 | 17.238 | 38.260 | 39.622 | 39.702 |
| Staff expenses | -381 | -1.529 | -2.432 | -5.576 | -10.055 | -15.090 | -19.757 | -26.321 |
| EBITDA | 56 | 3.403 | 323 | 1.699 | 7.183 | 23.169 | 19.865 | 13.381 |
| Depreciation & amort. | -0 | -70 | -344 | -889 | -1.065 | -1.228 | -2.229 | -4.248 |
| EBIT | 56 | 3.333 | -21 | 810 | 6.118 | 21.942 | 17.636 | 9.133 |
| Net financials | -72 | 14 | -4 | -398 | -595 | -459 | -1 | -774 |
| Profit before tax | -16 | 3.347 | -25 | 412 | 5.523 | 21.483 | 17.634 | 8.358 |
| Tax | 1 | 779 | 61 | 131 | 1.221 | 4.732 | 3.927 | 1.891 |
| Net profit | -17 | 2.569 | -86 | 281 | 4.302 | 16.751 | 13.707 | 6.467 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 4.007 | 14.444 | 23.025 | 23.913 | 30.951 | 42.518 | 81.089 | 127.580 |
| Equity | 127 | 2.695 | 3.109 | 3.390 | 7.692 | 24.443 | 38.151 | 44.618 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.880 | 11.718 | 19.866 | 20.499 | 23.258 | 18.075 | 42.863 | 82.784 |
| Total debt | 3.880 | 11.718 | 19.866 | 20.499 | 23.258 | 18.075 | 42.863 | 82.784 |
EBITDA margin
33.7%
This company
15.8%
Market median
+113% vs market
20182025
Equity ratio
35.0%
This company
38.2%
Market median
+8% vs market
20182025
Return on equity
14.5%
This company
18.4%
Market median
+21% vs market
20182025
Net profit margin
16.3%
This company
8.1%
Market median
+101% vs market
20182025
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
20182025
Debt / equity
1.86×
This company
0.62×
Market median
-200% vs market
20182025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-04-17 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SA Management | Management | 2024 | — | — |
PH Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Machpali ApS | Company | 90.0% | 90.0% | 2020 |
ESH Holding 2019 ApS | Company | 10.0% | 10.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PCohn Holding ApS
Øresund Pharma ApS Board members of Øresund Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Svend Aage Johansen | Management | 0 companies |
| Patrick Halborg Cohn | Chief Executive Officer | 0 companies |